Highlights and Quick Summary
- Share Based Compensation of Revenue for the quarter ending September 30, 2022 was 5136.39% (a 13289.96% increase compared to previous quarter)
- Year-over-year quarterly Share Based Compensation of Revenue increased by 3247.27%
- Annual Share Based Compensation of Revenue for 2021 was 142.73% (a -79.86% decrease from previous year)
- Annual Share Based Compensation of Revenue for 2020 was 708.68% (a 1244.74% increase from previous year)
- Annual Share Based Compensation of Revenue for 2019 was 52.7% (a Infinity% increase from previous year)
- Twelve month Share Based Compensation of Revenue ending September 30, 2022 was 100.99% (a 3.79% increase compared to previous quarter)
- Twelve month trailing Share Based Compensation of Revenue decreased by -29.24% year-over-year
Trailing Share Based Compensation of Revenue for the last four month:
| 30 Sep '22 | 30 Jun '22 | 31 Mar '22 | 31 Dec '21 |
|---|---|---|---|
| 100.99% | 97.3% | 126.92% | 142.73% |
Visit stockrow.com/BBIO
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Share Based Compensation of Revenue of BridgeBio Pharma, Inc.
Most recent Share Based Compensation of Revenueof BBIO including historical data for past 10 years.Interactive Chart of Share Based Compensation of Revenue of BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. Share Based Compensation of Revenue for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2022 | – | 5136.39% | 38.36% | 1423.97% | – |
| 2021 | 153.45% | 684.39% | 55.74% | 7267.75% | 142.73% |
| 2020 | 9955.74% | 217.78% | 0.0% | 0.0% | 708.68% |
| 2019 | 72.41% | 21.6% | 0.0% | 0.0% | 52.7% |
| 2018 | – | – | – | 0.0% | 0.0% |
| 2017 | – | – | – | – | 0.0% |
Business Profile of BridgeBio Pharma, Inc.
Sector: Healthcare
Industry: Biotechnology